Document is current

Any future updates will be listed below

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Crossref DOI link: https://doi.org/10.1007/s12026-016-8843-5

Published Online: 2016-07-23

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark